Mandatory notification of trade

7/1/2011 2:15 AM EST

Oslo, Norway, July 1, 2011

Clavis Pharma ASA (OSE: CLAVIS) announces that in accordance with the Employee
Share Option Plan, the Board of Clavis Pharma ASA has on 30 June 2011 awarded in
total 170,000 share options to the following primary insiders:

 Name                             Options Granted   Outstanding

 Olav Hellebø (CEO)                        50 000   675 000

 Ole Henrik Eriksen (COO)                  30 000   88 800

 Athos Gianella-Borradori (CMO)            30 000   230 000

 Gunnar Manum (CFO)                        30 000   88 800

 Tone Veiteberg (VP QA/RA)                 30 000   57 000



In addition 217,000 share options have been awarded to employees that are not
defined as primary insiders.

The share options have a strike price of NOK 43,60, equal to the closing trading
price of the shares at the date of awarding the share options.

The exercise period is from 1 July 2012 to 30 June 2014.

Following the grant the total number of share options outstanding is 1,856,200.


For further information contact:
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
 


This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.





[HUG#152